This alarming epidemiological trend has prompted a more proactive approach to obesity management, including a marked increase in prescriptions for anti-obesity medications (AOMs), such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs; including semaglutide). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.